Methods and compositions for treating infectious, autoimmune, and allergic disease

Inventors

Nagler, Cathryn R. • Bao, Riyue • Antonopoulos, Dionysios • COLSON, John W. • HESSER, Lauren Anders

Assignees

Clostrabio • University of Chicago

Abstract

Provided herein are methods and compositions for treating food allergies, infections, autoimmune conditions, and other allergic conditions. Also provided are methods for treating an infectious, autoimmune, or allergic disease in a subject comprising administering a composition comprising bacterium Anaerostipes caccae to the subject. Further aspects relate to a method for treating a food allergy or for reducing an allergic response to an allergen or for treating or preventing an anaphylactic response in a subject comprising administering a composition comprising bacterium Anaerostipes caccae and a prebiotic to the subject.

Core Innovation

Anaerostipes caccae is disclosed for microbiome-based treatment in a subject, including treatment of infectious, autoimmune, and allergic/atopic diseases. The document states that administering Anaerostipes caccae can treat or reduce an allergic/atopic disease state, including food allergy responses.

A therapeutic concept is described in which Anaerostipes caccae is administered together with a prebiotic to treat and/or reduce food allergy responses and to prevent and/or treat anaphylaxis. The prebiotic includes fermentable butyrate-releasing oligosaccharide and other described oligosaccharides/fibers, and the document links these compositions to butyrate production and microbiome-related dysbiosis.

The document also describes a diagnostic approach based on protective and non-protective OTU ratios, including a protective/non-protective OTU ratio of less than 3, for food allergy or other conditions. Supporting findings include nonclinical gnotobiotic mouse experiments in which A. caccae monocolonization and healthy-infant microbiota are protective against cow’s milk allergy/anaphylaxis to β-lactoglobulin, with associated biomarker reduction and reduced Th2 cytokines including IL-13 and IL-4.

The disclosed subject matter also compares gut microbiome composition across conditions such as Healthy and CMA, identifying multiple bacterial taxa/OTUs and associated UP indicators and values. It further focuses on Anaerostipes caccae, provides qPCR primer sequences and gene targets used for detection and quantification, and reports confirmation at the whole-genome level and SNP-based strain identity, together with the statement that the isolate does not possess virulence genes and shows antibiotic susceptibility.

Claims Coverage

The partial content provides two independent claims. Both claims are directed to increasing butyrate production in a dysbiosis-affected subject via administering compositions that include Anaerostipes caccae, with one claim additionally specifying potato starch and the other specifying lactate and acetate. No additional independent claims are provided in the partial content.

Across the two independent claims, the core inventive coverage is increasing butyrate production in dysbiosis by administering Anaerostipes caccae-containing compositions, either with potato starch or with lactate and acetate, with dependent claims further narrowing subject categories and administration context.

Stated Advantages

Documented Applications